This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Tang Prize Awarded for Immunotherapy
Tech award

Tang Prize Awarded for Immunotherapy

Analysis based on 9 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026

Sentiment
80
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The recognition of these scientists and their work in cellular immunotherapy by the Tang Prize highlights the transformative potential of these therapies for cancer treatment. This event is likely to increase investor confidence and research funding in the biotechnology and pharmaceutical sectors, particularly for companies involved in CAR-T and TIL therapies, such as Novartis. The continued expansion of CAR-T therapy into new areas like autoimmune diseases and cardiac injury repair also signals broader market opportunities.

Biotechnology Pharmaceuticals Healthcare
Event Summary

The 2026 Tang Prize in Biopharmaceutical Science has been jointly awarded to Drs. Steven Rosenberg, Michel Sadelain, and Carl H. June for their groundbreaking discoveries and development of tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR-T) therapies. These therapies utilize a patient's own immune cells to combat blood cancers and solid tumors, revolutionizing cancer treatment. Dr. Rosenberg's work at the United States — National Cancer Institute laid the foundation for adoptive cell therapy and demonstrated the efficacy of TILs. Drs. Sadelain and June were pivotal in developing CAR-T cell therapy, with Dr. Sadelain establishing the core architecture and Dr. June leading successful clinical trials and partnering with Novartis for the first FDA-approved CAR-T therapy, Tisagenlecleucel. The prize, established by Dr. Isaiah Samuel, recognizes significant contributions with a cash award and research grants, further promoting advancements in biopharmaceutical science.

Entities Involved
per
Steven Rosenberg
Dr. Steven Rosenberg is recognized as a joint laureate of the Tang Prize in Biopharmaceutical Science for his pioneering work in tumor-infiltrating lymphocyte (TIL) therapy and foundational clinical framework for adoptive cell therapy (ACT).
Importance 95.0 Sentiment 90.0
per
Michel Sadelain
Dr. Michel Sadelain is a joint laureate of the Tang Prize in Biopharmaceutical Science for his foundational advances in CAR-T cell therapy, including establishing the core architecture for FDA-approved CAR-T therapies and identifying CD19 as a therapeutic target.
Importance 95.0 Sentiment 90.0
per
Carl H. June
Dr. Carl H. June is a joint laureate of the Tang Prize in Biopharmaceutical Science for his key breakthroughs in CAR-T therapy, leading to its clinical success and the first FDA approval of Tisagenlecleucel.
Importance 95.0 Sentiment 90.0
oth
Tisagenlecleucel
Tisagenlecleucel is the first FDA-approved CAR-T therapy, a direct result of the work of the laureates and the partnership with Novartis, revolutionizing treatment for blood cancers.
Importance 65.0 Sentiment 75.0
stock
Novartis
Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.
Importance 60.0 Sentiment 70.0
govactor
United States — National Cancer Institute
The United States — National Cancer Institute is where Dr. Steven Rosenberg has served as Chief of the Surgery Branch since 1974, providing the institutional support for his foundational work in cancer immunotherapy.
Importance 40.0 Sentiment 60.0
per
Isaiah Samuel
Dr. Isaiah Samuel established the Tang Prize, providing the framework for recognizing significant scientific advancements like those in cellular immunotherapy.
Importance 20.0 Sentiment 60.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
United States — National Cancer Institute related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.